IL-17A Enhances Retinal Neovascularization
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24021747 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Brooklyn E Taylor und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Science, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. Hauptthemen laut MEDLINE: Retinal Neovascularization, Diabetic Retinopathy, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSRD VA, NEI NIH HHS, Cleveland Eye Bank Foundation.
Abstract (Originalsprache)
Retinal neovascularization occurs in proliferative diabetic retinopathy, neovascular glaucoma, and age-related macular degeneration. This type of retinal pathology normally occurs in the later stages of these ocular diseases and is a prevalent cause of vision loss. Previously, we determined that Interleukin (IL)-17A plays a pivotal role in the onset and progression of non-proliferative diabetic retinopathy in diabetic mice. Unfortunately, none of our diabetic murine models progress to proliferative diabetic retinopathy. Hence, the role of IL-17A in vascular angiogenesis, neovascularization, and the onset of proliferative diabetic retinopathy was unclear. In the current study, we determined that diabetes-mediated IL-17A enhances vascular endothelial growth factor (VEGF) production in the retina, Muller glia, and retinal endothelial cells. Further, we determined that IL-17A can initiate retinal endothelial cell proliferation and can enhance VEGF-dependent vascular angiogenesis. Finally, by utilizing the oxygen induced retinopathy model, we determined that IL-17A enhances retinal neovascularization. Collectively, the results of this study provide evidence that IL-17A plays a pivotal role in vascular proliferation in the retina. Hence, IL-17A could be a potentially novel therapeutic target for retinal neovascularization, which can cause blindness in multiple ocular diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Science, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
- Louis Stokes Cleveland VA Medical Center, Cleveland, OH 44106, USA.
ORCID-Profile: Thomas E Zapadka
Förderung
- CSRD VA
- NEI NIH HHS
- Cleveland Eye Bank Foundation
- National Eye Institute
- United States Department of Veterans Affairs
Zitieren
APA
Taylor, B. E., Lee, C. A., Zapadka, T. E., Zhou, A. Y., Barber, K. G., Taylor, Z. R. R., Howell, S. J., & Taylor, P. R. (2023). IL-17A Enhances Retinal Neovascularization. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24021747
Vancouver
Taylor BE, Lee CA, Zapadka TE, Zhou AY, Barber KG, Taylor ZRR, et al. IL-17A Enhances Retinal Neovascularization. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24021747
BibTeX
@article{Taylor2023,
author = {Taylor, Brooklyn E and Lee, Chieh A and Zapadka, Thomas E and Zhou, Amy Y and Barber, Katherine G and Taylor, Zakary R R and Howell, Scott J and Taylor, Patricia R},
title = {IL-17A Enhances Retinal Neovascularization},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24021747}
}
EUVIMED